Inactive

The 3D Tissue Bioprinting Laboratory (3DTBL) at the National Center for Advancing Translational Sciences (NCATS) is producing and using engineered tissues as physiological relevant assay platforms for... The 3D Tissue Bioprinting Laboratory (3DTBL) at the National Center for Advancing Translational Sciences (NCATS) is producing and using engineered tissues as physiological relevant assay platforms for predictive drugs screening. There is a need to purchase a new bioprinter which will be used to increase the capabilities of the group to develop biofabricated tissue models, including neuronal circuits of addiction and pain (HEAL program), neuromuscular junction (NMJ) tissue for muscular dystrophy-related diseases (potential application for gene therapy, like congenital myasthenic syndrome (CMS) for PaVe-GT program), and pain (HEAL program), vascularized lung models for the Antiviral Pandemic Program (APP), and tissue for the two programs funded by the RFA-TR-21-015. The purpose of this acquisition is to acquire one (1) of Regenhu’s 3D Bioprinting Station model R-GEN 200 or Equal that meet all salient characteristics.